Dopheide Julie A
Psychiatry and the Behavioral Sciences, University of Southern California, Schools of Pharmacy and Medicine, 1985 Zonal Ave, Los Angeles, CA 90089, USA.
Am J Manag Care. 2009 May;15(5 Suppl):S141-50.
Pharmacotherapy plays a primary role in the management of attention-deficit/hyperactivity disorder (ADHD), despite the availability of effective behavioral interventions. Psychostimulants are the most commonly prescribed form of pharmacotherapy for patients with ADHD and their benefits in managed care are severalfold, leading not only to symptom resolution and improved quality of life for patients, but also reduced costs for payers and purchasers. The use of these agents requires careful consideration and management by health plan stakeholders for optimal effectiveness. Concerns regarding medication adherence, in addition to the potential for diversion and abuse of psychostimulants, highlight the importance of effective pharmacotherapy management in patients with ADHD. Initiatives promoting medication adherence, such as patient/parent education, provider follow-up, and adverse effect management, are crucial for ensuring treatment success. Once-daily, extended-release formulations of stimulants may also contribute to improving medication adherence, as may managed care pharmacy interventions such as pharmacy database monitoring.
尽管有有效的行为干预措施,但药物治疗在注意力缺陷多动障碍(ADHD)的管理中仍起着主要作用。精神兴奋剂是治疗ADHD患者最常用的药物治疗形式,其在管理式医疗中的益处是多方面的,不仅能使患者症状得到缓解、生活质量得到改善,还能降低支付方和购买方的成本。这些药物的使用需要健康计划利益相关者进行仔细考虑和管理,以实现最佳疗效。除了精神兴奋剂有被转移和滥用的可能性外,对药物依从性的担忧凸显了ADHD患者有效药物治疗管理的重要性。促进药物依从性的举措,如患者/家长教育、提供者随访和不良反应管理,对于确保治疗成功至关重要。兴奋剂的每日一次缓释制剂也可能有助于提高药物依从性,管理式医疗药房干预措施如药房数据库监测也有同样作用。